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Abstract
Background: Changes in DNA methylation in the mammalian genome during development are frequent events and
play major roles regulating gene expression and other developmental processes. It is necessary to identify these events
so that we may understand how these changes affect normal development and how aberrant changes may impact
disease.
Results: In this study Methylated DNA ImmunoPrecipitation (MeDIP) was used in conjunction with a NimbleGen
promoter plus CpG island (CpGi) array to identify Tissue and Developmental Stage specific Differentially Methylated
DNA Regions (T-DMRs and DS-DMRs) on a genome-wide basis. Four tissues (brain, heart, liver, and testis) from C57BL/6J
mice were analyzed at three developmental stages (15 day embryo, E15; new born, NB; 12 week adult, AD). Almost
5,000 adult T-DMRs and 10,000 DS-DMRs were identified. Surprisingly, almost all DS-DMRs were tissue specific (i.e.
methylated in at least one tissue and unmethylated in one or more tissues). In addition our results indicate that many
DS-DMRs are methylated at early development stages (E15 and NB) but are unmethylated in adult. There is a very
strong bias for testis specific methylation in non-CpGi promoter regions (94%). Although the majority of T-DMRs and
DS-DMRs tended to be in non-CpGi promoter regions, a relatively large number were also located in CpGi in promoter,
intragenic and intergenic regions (>15% of the 15,979 CpGi on the array).
Conclusions: Our data suggests the vast majority of unique sequence DNA methylation has tissue specificity, that
demethylation has a prominent role in tissue differentiation, and that DNA methylation has regulatory roles in
alternative promoter selection and in non-promoter regions. Overall, our studies indicate changes in DNA
methylation during development are a dynamic, widespread, and tissue-specific process involving both DNA
methylation and demethylation.
Background
DNA methylation in mammals occurs predominantly at
CpG dinucleotides [1]. Early studies indicated that in
normal cells, most CpGs in repeats, retroviral sequences,
and within the coding region of genes are methylated,
whereas most CpG island (CpGi) regions are maintained
in an unmethylated state [2,3]. After fertilization there is
a period of genome-wide demethylation followed by per-
iods of remethylation in somatic cells after implantation.
Demethylation and reprogramming is also necessary in
the germ cells to reset gamete-specific imprinting [4-7].
There is a long history and generally inverse correlation
between gene promoter DNA methylation and gene
expression [8-12]. Early studies proposed that regulated
methylation and demethylation has a role regulating
gene expression during development [10,13].
The critical function of DNA methylation during devel-
opment is also apparent from the consequence of targeted
knockouts of DNA methyltransferase genes. The knockout
of Dnmt1, which has a strong preference for hemimethy-
lated DNA and is thus considered to be a maintenance
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any medium, provided the original work is properly cited.DNA methyltransferase, is lethal during development [14].
Dnmt3a and Dnmt3b are required for de novo methylation
during development [15]. The persistent expression of
both Dnmt 3a and Dnmt 3b after gastrulation and implan-
tation suggests that de novo methylation occurs during
later stages of development.
Restriction Landmark Genomic Scanning (RLGS)
detected differences in DNA methylation between tissues
more than 15 years ago [16-19]. These studies, as well as
more recent reports using a variety of methods, have
markedly altered our concept of differentially methylated
regions (DMRs) in the mammalian genome and the pro-
gression of DNA methylation changes during development
[19-36]. Tissue Specific Differentially Methylated Regions
(T-DMRs) include both CpGi and non-CpGi promoter
r e g i o n sa sw e l la si n t r a g e n i ca n di n t e r g e n i cr e g i o n s
[19,32,37,38]. Analysis of T-DMRs using a CpGi array
indicated that T-DMRs in CpGi regions are associated
with developmental gene loci and many are located in
non-promoter regions [23]. CpGi amplification in con-
junction with microarrays, indicated approximately 4% of
dense CpGi promoters are methylated in normal periph-
eral blood [31]. A number of studies have consistently
observed that weak or non-CpGi promoters are major tar-
gets for tissue specific DNA methylation [12,28,30,33,39].
Analysis of DNA methylation changes during develop-
ment in vitro and in vivo are more limited but indicate
that DNA methylation is a dynamic process involving
both methylation and demethylation [20,26,32]. In vivo
analysis of methylation changes within a tissue at differ-
ent developmental stages is complicated by changes in
cell populations [32]. In vitro analysis of DNA methyla-
tion during differentiation of ES cells or progenitor cells
is complicated by potential aberrant methylation due to
growth of cells in tissue culture [20,26,40].
Our previous results identified a limited number of
T-DMRs using RLGS, suggesting that methylation
changes during development are dynamic and involve
both methylation and demethylation [19,32]. The results
reported here investigate this with a more comprehen-
sive set of T-DMRs and Developmental Stage specific
Differentially Methylated DNA Regions (DS-DMRs)
identified through Methylated DNA ImmunoPrecipita-
tion (MeDIP) [20,32].
Results
MeDIP methylation analysis
The MeDIP methylation analysis developed by Weber et al
[33] was utilized to identify genomic sites of differential
DNA methylation in selected 12 wk adult C57BL/6J
mouse tissues (T-DMRs) and in tissues at different devel-
opmental stages (DS-DMRs: 15 day embryo, E15; new
b o r n ,N B ;a n d1 2w ka d u l t ,A D ) .M e t h y l a t e dD N Aw a s
immunoprecipitated with antibody to 5-methyl-cytidine,
the input and immunoprecipitated (IP) DNA were differ-
entially labeled and hybridized to a NimbleGen promoter
plus CpGi array according to a protocol provided by Nim-
bleGen. The NimbleGen Array covers all UCSC-annotated
CpGi (15,979) as well as promoters for all RefSeq genes
(19,530). Repetitive regions are excluded from the Array.
Non-CpGi intragenic and intergenic regions are not cov-
ered by the array except in some limited regions in which
the array is essentially a tiling array (1.9 Mb on portions of
chromosomes 6, 7, and 17).
Assessment of the MeDIP data quality and validation of
MeDIP methylation peaks
A number of methods were used to validate the quality of
the MeDIP methylation data. These include scatter plots
of log 2 ratios between IP DNA and input DNA, analysis
of Pearson Coefficients between biological replicate sam-
ples, comparison of MeDIP methylation with previously
identified RLGS T-DMRs, MeDIP analysis of other known
methylation sites, such as imprinted genes, and analysis of
both selected and randomly chosen MeDIP methylated
regions by Sequenom MassARRAY quantitative methyla-
tion analysis of bisulfite treated DNA. An example of a
selected region analyzed by Sequenom MassARRAY is
shown in Figure 1. The results indicate a close similarity
between MeDIP and Sequenom MassARRAY methylation
analysis. Additional details of Sequenom MassARRAY
methylation analysis and other validation methods are pre-
sented in the Methods section and Additional files.
Identification of genomic sites of DNA methylation in
adult tissues (brain, heart, liver, and testis)
The IP and input DNA from 12 wk adult C57BL/6J mouse
tissues (brain, heart, liver, and testis) were hybridized to a
NimbleGen Promoter plus CpGi array. T-DMRs are geno-
mic regions that are methylated in one or more of the four
adult tissues, but unmethylated in at least one tissue. For
the identification of T-DMRs, the log2 ratios of all probes
for each sample were normalized and used to identify
methylation peaks as described in the methods. To facili-
tate the analysis of MeDIP data, an ad hoc bioinformatics
tool was developed to process the methylation peak lists
for individual samples and identify genomic regions that
are 1) commonly methylated in all tissues; 2) methylated
in a single tissue; and 3) methylated in some but not all
tissues. Only those methylation peak regions that were
present in both biological replicate samples and were
absent from at least one other tissue were designated as
T-DMRs. Thus, the frequency of T-DMRs may be under-
estimated. T-DMR locations were designated as 1) CpGi
Promoter; 2) Intragenic CpGi; 3) Intergenic CpGi; and 4)
Non-CpGi promoter (see details in Methods).
Summaries of the number and distributions of the
adult T-DMRs are shown in Table 1. Overall, there are
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Page 2 of 16almost 5,000 adult T-DMRs that are present in one or
more of the examined adult tissues but are absent in
one or more tissues, whereas there are only 460 methy-
lated regions that are common to all four tissues. There
are a relatively high number of T-DMRs unique to testis
(1,294) and a relatively low number unique to brain
(285). Most of the T-DMRs (69.3%) are located within
non-CpGi promoter regions, but 30.7% are within CpGi
regions, among which 13.7% are within CpGi promoter
regions and 17% are in non-promoter CpGi regions
(intragenic and intergenic CpGi regions). Within the dif-
ferent tissues there are some notable differences. For
CpG island
Transcript
Transcript Start
Liver 1
Liver 2
Testis 2
Testis 1
ES 1
ES 2
Scaled 
log2 ratio
Stk31
Sequenom Methylation Analysis
Methylated Testis
Liver 2
Testis 2
ES 1
ES 2
Testis 1
0 
Liver 1
100% Not analyzed 
Figure 1 Comparison of methylation data between MeDIP/NimbleGen Promoter + CpGi Array and Sequenom MassArray: Stk31 CpGi
promoter region. The Stk31 gene region with a CpGi promoter region that is methylated in the liver, but not in ES or testis cells. The box
indicates the position of the methylation peak in the liver that overlaps with the CpGi promoter region analyzed by Sequenom. In the epigram
of Sequenom methylation analysis shown at the bottom panel, the blue circles indicate 100% methylation, green circles indicate around 50%
methylation and yellow circles indicate 0% methylation. The results from biological duplicate samples are shown. The bottom lane (Sequenom
Methylation Analysis) shows the results of analysis of testis DNA after in vitro methylation using M. Sss1 methylase (New England Biolabs).
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T-DMRs are in non-CpGi promoter regions, whereas
each of the three somatic tissues is no more than 60%.
T-DMRs that are present in brain, heart, and liver, but
not testis, would include somatic methylation sites. The
majority of these (B+H+L) are in CpGi regions (64.3%).
The number and distribution of T-DMRs in ES cells
ES cells are derived from the inner cell mass of the early
blastocyst that gives rise to the embryo. Following fertiliza-
tion, the embryonic cells undergo a period of demethyla-
tion and make up/form the inner cell mass. Remethylation
of somatic tissues is thought to resume following implan-
tation [7]. Thus, we compared the methylation status of
T-DMRs in E15 tissues with ES cells (Additional file 1).
Overall, there are fewer T-DMRs (2750) from the compar-
ison of ES cell and E15 tissues than T-DMRs in adult tis-
sues (4686, Table 1). We found more unique methylation
peaks in ES cells (981) than in E15 tissues of brain (310),
heart (131), liver (764), or testis (230). This indicates that
there are many sites that are methylated in ES cells but are
unmethylated in E15 tissues with most (85.5%) located in
non-CpGi promoter regions.
T-DMRs in regions outside CpGi regions and promoters
The NimbleGen promoter + CpGi array contains a tiling
array that covers about 1.9 Mb of the mouse genome. This
includes the Hoxa gene cluster on chromosome 6 (423 Kb),
the Igf2r imprinted region on chromosome 17 (88 Kb) and
imprinted regions on chromosome 7 (1,390 Kb). In these
regions it is possible to identify tissue specific methylation
peaks that are not associated with CpGi regions or promo-
ters. For example, in the KvDMR region on chromosome 7
(Additional file 2), there are non-CpGi and non-promoter
methylation peaks in testis and brain that are not present in
liver in addition to T-DMRs in CpGi regions. The results
shown in Additional file 3a indicate that there is similar dis-
tribution of T-DMRs in the tiling regions in CpGi and non-
CpGi promoter regions as in the rest of the array-covered
genome. However, there are additional methylation peaks
within the tiling regions (Additional file 3b) in non-CpGi
intragenic regions (15.7%) and in non-CpGi intergenic
regions (12.9%). These results indicate that almost 30% of
the T-DMRs may be missed by restricting analysis to CpGi
and promoter regions.
Developmental Stage-Specific Differentially Methylated
Regions (DS-DMRs)
We used MeDIP to determine the number and location of
methylated sites at the different developmental stages
within each tissue (Table 2). DS-DMRs are genomic regions
that are methylated at one or more developmental stage of
a tissue, but unmethylated in at least one stage. It should be
noted that DS-DMRs are selected as stage-specific differen-
tially methylated regions within a tissue without regard to
presence or absence in another tissue. This analysis pro-
vides a basis for determining changes in developmental
stage specific methylation that occur within a tissue. These
changes may reflect active or passive changes in DNA
methylation as well as changes in the proportion of specific
cell populations. The Pearson Coefficients between the
duplicate biological replicates varied somewhat from
Table 1 Adult T-DMRs
Tissue Total CpGi Prom % Non-CpGi Prom % Intra-genic CpGi % Inter-genic CpGi %
Common 460 18 3.9 230 50.0 163 35.4 49 10.7
Brain unique 285 68 23.9 173 60.7 23 8.1 21 7.4
Heart unique 822 223 27.1 428 52.1 115 14.0 56 6.8
Liver unique 711 155 21.8 428 60.2 66 9.3 62 8.7
Testis unique 1294 44 3.4 1215 93.9 20 1.5 15 1.2
Total T-unique 3112 490 15.7 2244 72.1 224 7.2 154 4.9
B+H 482 69 14.3 282 58.5 89 18.5 42 8.7
B+L 12 2 16.7 7 58.3 2 16.7 1 8.3
B+T 26 1 3.8 25 96.2 0 0.0 0 0.0
H+L 49 7 14.3 24 49.0 13 26.5 5 10.2
H+T 47 0 0.0 45 95.7 2 4.3 0 0.0
L+T 305 3 1.0 268 87.9 27 8.9 7 2.3
B+H+L 414 65 15.7 148 35.7 127 30.7 74 17.9
B+H+T 175 3 1.7 151 86.3 19 10.9 2 1.1
B+L+T 18 0 0.0 15 83.3 2 11.1 1 5.6
H+L+T 46 4 8.7 37 80.4 4 8.7 1 2.2
Total
multi-tissues 1574 154 9.8 1002 63.7 285 18.1 133 8.4
Total T-DMRs 4686 644 13.7 3246 69.3 509 10.9 287 6.1
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Page 4 of 16Table 2 The number of DS-DMRs in different tissues
Total Adjusted
# %
1 CpGi-Prom %
2 non-CpGi-Prom %
2 Intra-genic CpGi %
2 Inter-genic CpGi %
2
Brain:
Common 1903 NA ND 182 9.6 1018 53.5 493 25.9 210 11.0
E15_uniq 533 533 27.5 105 19.7 359 67.4 35 6.6 34 6.4
E15+NB 490 509 25.3 66 13.5 368 75.1 29 5.9 27 5.5
NB_uniq 370 400 19.1 55 14.9 248 67.0 42 11.4 25 6.8
AD_uniq 408 532 21.1 94 23.0 233 57.1 52 12.7 29 7.1
NB+AD 70 82 3.6 5 7.1 40 57.1 16 22.9 9 12.9
E15+AD 65 77 3.4 11 16.9 46 70.8 7 10.8 1 1.5
Total* 1936 2132 100.0 336 15.2 1294 62.6 181 13.9 125 8.4
UnMe-AD** 1393 1442 72.0 226 16.2 975 70.0 106 7.6 86 6.2
Me-AD*** 543 691 28.0 110 20.3 319 58.8 75 13.8 39 7.2
Heart:
Common 1844 NA ND 218 11.8 946 51.3 491 26.6 189 10.2
E15_uniq 46 81 6.9 27 58.7 8 17.4 2 4.3 9 19.6
E15+NB 87 125 13.0 17 19.5 61 70.1 4 4.6 5 5.7
NB_uniq 93 112 13.9 12 12.9 64 68.8 7 7.5 10 10.8
AD_uniq 172 172 25.6 45 26.2 83 48.3 33 19.2 11 6.4
NB+AD 246 253 36.7 44 17.9 132 53.7 54 22.0 16 6.5
E15+AD 27 34 4.0 6 22.2 15 55.6 5 18.5 1 3.7
Total* 671 777 100.0 151 22.4 363 54.1 105 15.6 52 7.7
UnMe-AD** 226 318 33.7 56 24.8 133 58.8 13 5.8 24 10.6
Me-AD*** 445 459 66.3 95 21.3 230 51.7 92 20.7 28 6.3
Liver:
Common 1497 NA ND 141 9.4 726 48.5 425 28.4 205 13.7
E15_uniq 117 119 4.9 25 21.4 74 63.2 10 8.5 8 6.8
E15+NB 1419 1431 60.0 198 14.0 1034 72.9 125 8.8 62 4.4
NB_uniq 147 147 6.2 24 16.3 109 74.1 8 5.4 6 4.1
AD_uniq 468 813 19.7 70 15.0 322 68.8 45 9.6 31 6.6
NB+AD 36 46 1.5 2 5.6 30 83.3 3 8.3 1 2.8
E15+AD 194 249 8.1 13 6.7 130 67.0 31 16.0 20 10.3
Total* 2381 2804 100.0 332 13.9 1699 71.4 222 9.3 128 5.4
UnMe-AD** 1683 1696 70.7 247 14.7 1217 72.3 143 8.5 76 4.5
Me AD*** 698 1107 29.3 85 12. 482 69.1 79 11.3 52 7.4
Testis:
Common 570 NA ND 20 3.5 363 63.7 148 26.0 39 6.8
E15_uniq 272 380 6.3 105 38.6 101 37.1 33 12.1 33 12.1
E15+NB 939 1094 22.0 193 20.6 480 51.1 157 16.7 109 11.6
NB_uniq 798 789 18.4 231 28.9 391 49.0 86 10.8 90 11.3
AD_uniq 2214 2336 50.9 71 3.2 1908 86.2 165 7.5 70 3.2
NB+AD 63 65 1.4 3 4.8 48 76.2 9 14.3 3 4.8
E15+AD 62 91 1.4 5 8.1 38 61.3 14 22.6 5 8.1
Total 4348 4755 100.0 608 14.0 2966 68.2 464 10.7 310 7.1
UnMe-AD** 2009 2263 40.8 529 26.3 972 48.4 276 13.7 232 11.5
Me-AD*** 2339 2493 47.6 79 3.4 1994 85.3 188 8.0 78 3.3
Grand Total:
Common 5814 NA ND 561 9.6 3053 52.5 1557 26.8 643 11.1
DS-DMRs 9336 10469 100.0 1427 15.3 6322 67.7 972 10.4 615 6.6
UnMe-AD** 5311 5719 56.9 1058 19.9 3297 62.1 538 10.1 418 7.9
Me-AD*** 4025 4750 43.1 369 9.2 3025 75.2 434 10.8 197 4.9
%
1: percentage is based on the row total vs. total DMRs; %
2: percentage is based on the total of DMRs in the row; Total*: Stage specific; UnMe-AD**:
unmethylated in AD but methylated in E15 and/or NB; Me-AD***: methylated in Adult but unmethylated in E15 and/or NB; Adjusted#: number of DMRs adjusted
based on the adjusted coefficiency between the duplicated samples.
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Page 5 of 16sample to sample (Additional file 4). Therefore the total
number of methylation peaks would be somewhat underes-
timated in samples with low relative to those with high
Pearson Coefficients. We adjusted the total number of
methylation peaks as if the Pearson Coefficients for all
s t a g e sw e r et h es a m ea st h eb e s to n ei nt h a tt i s s u e( s e ed a t a
labeled “Adjusted” in Table 2). Although the total number
of peaks increases for the samples with lower Coefficients,
the overall trends are comparable (Table 2 and Figure 2),
indicating that our underestimation of methylation peaks
does not have a significant impact on the distribution of
methylation peaks into different genomic regions.
T h e r ew e r ec o n s i d e r a b l ym o r em e t h y l a t i o ns i t e st h a t
were common within a tissue at the different develop-
mental stages than between different adult tissues (460
common sites, Table 1). Brain, heart, and liver each had
1,903, 1,844 and 1,497 common methylation sites,
respectively, whereas testis had 570 (Table 2). Similar to
the common sites for the adult tissues, about 50% of
developmental stage common sites are in CpGi regions
(CpGi promoter + intragenic and intergenic CpGi) and
about 50% are in non-CpGi promoter regions (Table 1
and 2). Somewhat surprising is the relatively high num-
ber of sites in liver (and brain and testis, to some
degree) that are methylated in E15 + NB but unmethy-
lated in adult (1,419). Together, in somatic tissues
(heart, brain, and liver), there were almost 5,000 sites of
methylation that exhibit stage specific differences. Testis
alone had 4,348 sites of stage specific methylated
regions, most of which were methylated in adult and
localized to non-CpGi promoters. Again, as for the
adult tissues, the most frequent location for differential
methylation was within non-CpGi promoter regions
(54.1% to 71.4%), followed by CpGi promoter regions
(13.9 to 22.4%), intragenic CpGi regions (9.3 to 15.6%),
and intergenic CpGi regions (5.4 to 8.4%). In contrast to
other tissues, the location of testis stage specific DS-
DMRs appear to shift from a high proportion of CpGi
location at early developmental stages (E15, 62.9% and
NB, 51.0%) to a high proportion of non-CpGi promoter
location in adult (86.2%).
Many DS-DMRs are unmethylated in adult
We grouped the DS-DMRs within a tissue according to
whether they were unmethylated in adult (UnMe-AD)
but methylated at earlier developmental stages (E15, E15
+NB, NB). These would represent sites of demethylation
during development. Conversely sites that were methy-
lated in adult (E15+AD, NB+AD, AD) but unmethylated
at earlier developmental stages would be sites that were
methylated during development. Surprisingly, there were
more sites that became unmethylated (5,311) than
became methylated (4,025) during development (Figure 2
and Table 2). Adjustment for differences in the Pearson
Coefficient (Figure 2) does not significantly alter this gen-
eral conclusion. Among the different tissues, there seem
to be some significant differences with regard to the ratio
of DMRs subjected to methylation and demethylation. In
testis, there are an almost equal number of sites that
become unmethylated (2,009) or methylated (2,339) in
adult. However, in brain and liver there are a much larger
number of sites undergoing demethylation in adult than
that of methylation whereas in heart, there are a smaller
number of sites undergoing demethylation than methyla-
tion. These results indicate dynamic changes in DNA
methylation during developm e n ta n dt h a te p i g e n e t i c
changes resulting in unmethylated DS-DMRs are a major
feature of differentiation into adult tissues.
Overlap between DS-DMRs in different tissues
The DS-DMRs indicate differential stage-specific sites of
methylation within a tissue without regard to whether it is
tissue specific. To determine how many of the DS-DMRs
are tissue specific, we determined the extent of overlapping
DS-DMR (i.e., methylation) between tissues (Table 3). The
results indicate for all four tissues together, the majority
(7,857 or 80.3%) of the 9,784 DS-DMRs are unique to a
single tissue whereas the remaining 1,927 DS-DMRs are
present in two or more but not all tissues, and thus are
also tissue-specific. Together, it indicates that all of the
9,784 DS-DMRs are also T-DMRs. If testis is excluded,
there are 4,232 out of 5,519 DS-DMRs that are unique to a
single tissue and 613 peaks being present from one or
more but not all tissues (Additional file 5a). In this case, we
did find a small number of peaks (21) that are common to
500
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Figure 2 DS-DMRs: Number of peaks that are Unmethylated or
Methylated in adult Tissues. Total numbers of unmethylated
peaks and methylated peaks are shown in adult heart, brain, liver
and testis. The grey bar indicates the actual total number of
unmethylated and methylated peaks in each tissue. The black bar
indicates total number of unmethylated and methylated peaks in
each tissue after adjustment for differences in the Pearson
Coefficient.
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more commonality among each other than with testis. We
also examined the overlap for the 5,761 DMRs that are
common to all stages in a tissue (Additional file 5b). The
majority of these DMRs are also tissue-specific (5,487/
5,761 or 95.2%). However, compared to DS-DMRs, the per-
centage of these DMRs being tissue-unique is much lower,
approximately 15% for each of the somatic tissues and only
1.9% for testis. Only a small proportion (274 or 4.8%) are
common to all developmental stages and all tissues. Over-
all, since all of the 9,784 DS-DMRs and 5,487 of the 5,761
DMRs common to all developmental stages in a tissue are
also T-DMRs, we identified a total of 15,271 T-DMRs.
Tissue-Specific differences in DNA methylation within the
Hoxa gene cluster
Homeobox genes have important roles in regulating devel-
opment [41,42]. One of the tiled regions available on the
NimbleGen array includes the Hoxa gene cluster on chro-
mosome 6. Additional file 6 shows the scaled log2 ratios
from the NimbleGen SignalMap view of an approximately
100 Kb region that includes the Hoxa gene cluster. There
are 8 adult T-DMRs in this region that were present in
both biological replicate DNA samples of the involved tis-
sue(s). Even though this region is CpGi rich, none of the
peaks were within CpGi regions and only one was loca-
lized in a promoter region (Additional file 7; peak 7,
Hoxa7). The other methylation peaks were within introns
(peaks 2, 3, and 4) or associated with the 3’ end (exon) of
the gene (peaks 1, 5, 6, and 8). Four of the peaks (peaks 2-
5) were testis specific, one (peak 6) was heart specific, one
(peak 7) was present in heart and liver, and one (peak 8)
was in heart and brain. All sequences corresponding to
these peaks were highly conserved, suggesting a regulatory
function. Analysis of methylation differences within the
Hoxa gene cluster during development (Figure 3) indicates
that two additional DS-DMRs not seen as T-DMRs for
adult tissues were observed when samples from all three
developmental stages were examined (Additional file 6;
Additional file 7). One of these is specific to NB liver
(peak N1) and the other is a large region (peak N2) methy-
l a t e di nE 1 5a n dN Bo fl i v e ra n dt e s t i sa n di nA Dh e a r t ,
and demethylated in adult liver and testis. Overall, our
results indicate extensive tissue and developmental stage
specific methylation in the Hoxa gene cluster that is not
associated with promoter or CpGi regions.
DNA methylation within the Protocadherin gene cluster
Protocadherins are a large gene family involved in cell
adhesion and signaling, particularly during neural devel-
opment. There are three large clusters totaling more
than 50 genes (alpha, beta and gamma) that span about
1 MB on Chromosome 18 in the mouse. Additional file
8 shows the MeDIP methylation profile from a portion
of the Pcdha and Pchdhg gene clusters. Many of the
alternative promoters are associated with CpG islands.
Most of the alternative promoters are completely
unmethylated in the adult testis, but some are differen-
tially methylated in the liver (Pcdhga3 and Pcdhgb2,
peaks 8 and 11; Additional file 8 and Additional file 9).
Note that the promoter for Pcdhga6 (peak 13) is methy-
lated in the testis but unmethylated in liver, brain, and
heart. These results indicate that alternative promoters
within the Protocadherin gene cluster are targets for
DNA methylation.
Relationship between T-DMRs/DS-DMRs and gene
expression
To test whether the T-DMRs and DS-DMRs have any
relationship with and the expression of their associated
genes, we identified (from NCBI GEO database) and
analyzed two published expression data sets, which have
the best match to the samples we used in this study
with regard to animal strain, tissue type and develop-
mental stage.
For T-DMRs, we used GSE9954 [43] designed for the
analysis of 22 different tissues from adult C57BL/6 mice,
and we performed a small-scale manual examination, as
well as computational analysis for all T-DMRs. Manual
examination of individual genes revealed a variety of situa-
tions, with no obvious consistent pattern, likely due to rea-
sons discussed later. Nevertheless, the data from the
analysis of all T-DMRs seems to reveal two general trends:
1) Genes containing T-DMRs in non-CpGi promoters
tend to have lower expression in the tissue to which the
T-DMRs are unique than in other three tissues (Addi-
tional file 10 panel A-C); 2) Within the same tissue, genes
containing T-DMRs in non-CpGi promoters have lower
expression than those containing T-DMRs in either in
CpGi promoters or in intragenic CpGi and those contain-
ing no T-DMRs (Additional file 10 panel D). The first
trend is well shown in brain and liver, but less consistent
in heart and brain, while the second trend is consistently
observed in all four tissues. T-DMRs in CpGi promoters
do not seem to associate with a significantly lower expres-
sion except for those from liver, while T-DMRs in intra-
g e n i cC p G id on o ts e e mt oh a v eas i g n i f i c a n ti m p a c to n
Table 3 Overlap among DS-DMRs from different tissues
Tissue all DS-DMRs Tissue-Unique Multiple tissues# T-DMR%
Brain 1973 1065 908 100
Heart 867 533 334 100
Liver 3570 2160 1410 100
Testis 5469 4099 1370 100
Total 11879*/9784** 7857 4022*/1927**
#: peak present in 2 or more but not all tissues; *: contains redundancy due to
overlap; The numbers are larger than those in Table 2 due to certain peak
splitting; **: a non-redundant (unique) list of all sites from the four tissues.
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Page 7 of 16gene expression either way in any tissue examined. The
trend for DS-DMRs, based on analysis of a liver develop-
ment expression data set (GSE13149 [44]), seems to be
less clear except for adult unique DS-DMR, which are
mostly T-DMRs as described earlier and show a similar
pattern as T-DMRs (data now shown), suggesting that
there might be some differences between T-DMRs and
DS-DMRs in the ways they impact gene expression.
Discussion
Total number of T-DMRs and DS-DMRs
MeDIP methylation analysis in conjunction with Nim-
bleGen promoter + CpGi microarrays were used to
identify adult tissue specific differentially methylated
regions (T-DMRs) and developmental stage specific
DMRs (DS-DMRs). We used relatively conservative cri-
teria to identify methylation peaks requiring both
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Page 8 of 16independently derived biological replicates to contain
the same or overlapping methylation peaks. Other inves-
tigators have indicated that MeDIP may miss differen-
tially methylated regions in regions of low CpG density
[45]. Thus we may underestimate the total number of
T-DMRs and DS-DMRs to some extent. Nevertheless,
our study identified almost 5,000 adult T-DMRs and
10,000 DS-DMRs that represent a total of over 15,000
T-DMRs in four adult tissues (brain, heart, liver, and
testis; Tables 1 and 2). Since tissues are made up of
many cell types and it is likely that there are cell type
specific epigenetic differences, the methylation peaks we
identified probably correspond to the major cell types in
the tissue, while many methylation peaks corresponding
to minor cell types would be missed. Considering that
we only sampled 4 tissues and 3 developmental stages
(E15, NB, AD), and that the analysis does not include
methylation peaks in regions outside promoter and
CpGi regions (except in tiling regions), it is quite likely
that there are many additional T-DMRs and DS-DMRs
that were not identified in this study. These results
demonstrate that there are numerous DNA methylation
differences between adult tissues (T-DMRs) and within
t h es a m et i s s u ea td i f f e r e n ts t a g e so fd e v e l o p m e n t( D S -
DMRs), indicating that alterations in DNA methylation
are a major feature of development.
Genomic locations of T-DMRs and DS-DMRs
Overall most T-DMRs and DS-DMRs (about 70%) are
located within non-CpGi promoter regions (Table 1 and
2), which is consistent with results of other studies
[12,28,30,33,39]. However, we also found that about 30%
of T-DMRs (1,440/4,686) and DS-DMRs (3,014/9,336)
are located in CpGi regions (i.e. the sum of all CpGi-
associated DMRs vs. the total number of DMRs; Table 1
and 2). This corresponds to more than 15% of the
15,979 CpGi regions on the NimbleGen array and is a
relatively large number considering the limited number
of tissues and developmental stages surveyed and other
factors cited above. In fact, among the 15,979 CpGi
regions annotated in UCSC mm8 freeze, a total of 5,523
(34.6%) were partially or entirely methylated in one or
more of the 24 samples analyzed in this study (4 tissues
each with duplicated samples for 3 developmental
stages; data not shown). Thus, tissue- and developmen-
tal stage-specific CpGi methylation may be a very com-
mon event during development.
Analysis of methylation in the few tiling regions avail-
able on the NimbleGen array made it possible to deter-
mine whether there was significant tissue specific
methylation outside of promoter and CpG island regions.
Our results indicate that as much as 30% of the T-DMRs
are missed by restricting analysis to promoter and CpGi
regions (Additional file 3b).
The location of methylation peaks differs according to
tissue distribution. About 50% of the adult common
methylation sites are within CpGi regions whereas only
30% of the T-DMRs are located within CpGi regions
(Table 1). Similarly, about 48% of the methylation peaks
that are common among all developmental stages within
a tissue are located in CpGi regions (Table 2).T h es i g -
nificance of this difference between common methyla-
tion and differential methylation is not presently clear.
Possibly this reflects a difference between transient
changes in methylation that are tissue specific and more
stable changes in methylation that are common to
tissues.
The distribution of the location of T-DMRs and DS-
DMRs in testis is dramatically different from somatic
tissues. Almost 94% of the adult testis T-DMRs are
associated with non-CpGi promoter regions (Table 1
and 2). About 68% of the testis DS-DMRs are associated
with non-CpGi promoter regions, which represents an
average of E15, NB, and AD developmental stages.
Unlike somatic tissues there appears to be a clear pat-
tern shift in the distribution of testis DS-DMRs during
development. In E15 testis only about 37% of the DS-
DMRs are located in non-CpGi promoters whereas the
percentage increases in NB (49%) and AD (86%). This
may reflect post-natal onset of meiosis and other devel-
opmental changes. This general bias of DMRs towards
non-CpGi promoter vs. CpGi promoter is significant
since the majority (10,915 or 68.5%) of 19,528 promo-
ters (all RefSeqs promoters included in the array) are
CpGi promoters (based on our criteria region of 1kb
flanking each side of transcription start site).
T-DMRs correspond to sites of methylation that vary
between tissues, whereas DS-DMRs correspond to sites
of methylation within a single tissue that differ accord-
ing to developmental stage. We determined the extent
of overlap between DS-DMRs from different tissues by
combining all DS-DMRs for the same tissue and exclud-
ing common methylation sites within a tissue (Table 3
and Additional file 5a and 5b). We reasoned that the
degree of overlap of DS-DMRs among tissues would
shed light on the level of tissue specificity of DNA
methylation during development. We found a very low
level of overlap among different tissues (1,927/9,784 or
13.2%), indicating that most DS-DMRs are tissue-unique
and tissue-specific (Table 3). Even for DMRs that are
shared among all three developmental stages in a tissue
(Additional file 5b), almost 50% are tissue unique and
almost all are tissue specific (95.2%). In addition, a large
fraction of the tissue specific DS-DMRs were unique to
a single tissue (7,857/9,784 or 80%). However, we would
expect this percentage to decrease as more tissues are
added to the analysis. These results suggest that almost
all DNA methylation in non-repetitive regions is tissue
Liang et al. BMC Genomics 2011, 12:231
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methylation of some genomic regions containing repeti-
tive sequences is also tissue-specific [32].
Recent studies [22,25] identified 16,379 T-DMRs in four
human adult tissues (brain, liver, spleen, and colon) using
a method termed “Comprehensive High-throughput
Arrays for Relative Methylation” or CHARM. Although
the methods, species and tissues used for this analysis
were different from those presented here, the total number
of T-DMRs is surprisingly similar (15,271 vs. 16,379),
emphasizing extensive tissue specific DNA differences in
DNA methylation. However, the CHARM analysis of
human tissues found that 76% of the T-DMRs were
located within 2 kb of CpGi regions that were denoted
CpGi shores. The array design used in our study limits
analysis to promoter, CpGi regions, and very limited tiled
genomic regions and would appear to exclude most CpGi
shores. However, we reason that many CpGi shores may
be within the promoter regions in our studies. For both
the promoter and tiling regions, we observed a slightly
higher density of DS-DMRs in CpGi shores than in CpGi
regions (data not shown). Since at the genome scale, the
CpGi shore region is much larger (~6X) than the CpGi
region, we can expect to have a larger number of DS-
DMRs in the CpGi shores than in the CpGi, supporting
the conclusion of Irizarry et al [25] in principle that there
are more T-DMRs in CpGi shores.
Gene ontology of T-DMRs and DS-DMRs
Gene ontology (GO) analysis was performed to identify
any common theme among the identified T-DMRs. In
this analysis, we divided all DMRs associated with genes
into three groups (non-CpGi promoter, CpGi promoter,
and intragenic CpGi), since as noted by others [37,38],
methylation in different gene locations may impact the
gene expression regulation differently. We found more
or less similar enrichment categories for different
tissues, especially among somatic tissues. For both
T-DMRs and DS-DMRs, the most consistent GO
enrichment pattern is seen among those in non-CpGi
promoters (Additional file 11 and Additional file 12)
with enrichment for “membrane proteins, G-proteins,
olfactory proteins” among UnMe-AD (DS-DMRs) and
“extracellular space/region” for both T-DMRs and DS-
DMRS (Me-AD). Apparently, these enrichment patterns
reflect a pattern that is observed for all genes with non-
CpGi promoters (data not shown). Additional GO
enrichment was observed for somatic DS-DMRs in
intragenic CpGi regions on “regulation of biological and
cellular processes, ion-binding and transport”. This data
supports the notion that intra-genic CpGi methylation
tends to promote the expression of the involved gene
[46,47], and may participate in gene regulation during
differentiation and development.
“Demethylation” of previously methylated sites (DS-
DMRs) is a common feature of tissue differentiation
Quite surprisingly, our studies indicate that many DS-
DMRs that are methylated at early stages of development
(E15 and NB) are unmethylated in adult tissues (Table 2
and Figure 2). This is particularly evident in brain and
liver where there are almost 3 times as many DS-DMRs
that become “unmethylated” in adult as become “methy-
lated” in adult. This is somewhat contrary to expectations
that differentiation into adult tissues would reflect pro-
moter methylation and silencing of genes not associated
with the final gene expression pattern. In contrast, it sug-
gests that the final gene expression pattern depends on
extensive demethylation events during differentiation.
Although methylation of gene promoter regions is asso-
ciated with gene repression, gene body methylation is
associated with gene expression [37,38,48]. In addition,
recent reports indicate that there are extensive allelic dif-
ferences in gene expression in human that result from
allelic differences in methylation, due to imprinting or
DNA sequence variation [49,50]. Thus, demethylation of
previously methylated sites could reflect either increased
or decreased gene expression, depending on site location.
Our observations that demethylation is a common fea-
ture of tissue differentiation are consistent with the
recent report that liver development in human is charac-
terized predominantly by demethylation [20].
Methylation of ES cells
ES cells are pluripotent and are derived from the blasto-
meres of the early embryo that are thought to be exten-
sively demethylated due to active and passive
demethylation that follows fertilization. Therefore, we
decided to compare the methylation peaks from ES cells
with those found in E15 embryonic tissues (brain, heart,
liver, and testis) to determine the extent of methylation
differences during early stages of tissue differentiation
(Additional file 1). We found that the number of E15 T-
DMRs (1,769) is less than half of that found in adult
(4,686), which is consistent with E15 tissues being gener-
ally less methylated than adult. ES cells also had a low
level of methylation with 981 T-DMRs. However, some-
what surprisingly, ES cells had more methylation peaks
(981, Additional file 1) than any of the E15 tissues. This
would suggest that many genomic sites that are methy-
lated in ES cells become demethylated during early devel-
opment. We previously found that many (60%) of the
adult T-DMRs identified by RLGS were methylated in ES
cells, suggesting these were demethylated during tissue dif-
ferentiation [32]. It is also possible that some or many of
the sites that are methylated in ES cells are due to growth
in tissue culture. It has previously been shown that tumor
cells grown in tissue culture accumulate excessive aberrant
methylation that is unrelated to tumorigenesis [40]. Also,
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extended passages results in aberrant methylation [26] and
investigators found extensive differences in the genomic
methylation patterns of independently isolated human ES
cell lines [20]. At the present time, it is unclear whether
sites of methylation in ES cells is aberrant due to extended
growth in culture or whether demethylation during early
differentiation in ES cells is an important process as in
later stages of tissue differentiation noted above.
Methylation analysis of stem cells revealed extensive
Cytosine methylation in a non-CpG context [35,48,51]
that was mainly located within gene bodies [35]. The
non-CpG methylation appears to be mostly confined to
stem cells and disappears upon differentiation. Our ana-
lysis of mouse ES cells indicated a very low level of
intragenic CpGi methylation. This suggests that most of
the non-CpG gene body methylation was in non-CpGi
intragenic regions that were not on the NimbleGen
array or that our analysis did not resolve non-CpG
methylation.
Non-Promoter and non-CpGi methylation in the Hoxa
gene cluster
A 100 Kb region on chromosome 6 that includes the
Hoxa gene cluster is essentially a tiling array on the Nim-
bleGen promoter plus CpGi array. This region includes
16 RefSeq genes and 22 UCSC-annotated CpGi regions
(Additional file 6). Somewhat surprisingly all 8 methyla-
tion peaks were in non-CpGi regions and only one was in
a promoter region (Additional file 6 Additional file 7). In
addition, developmental analysis of Hoxa gene methyla-
tion indicated stage-specific methylation differences
(Figure 3). These differentially methylated regions
include 3’ exons and intron regions. Since these regions
a r eh i g h l yc o n s e r v e da n dHox genes are known to have
important roles in development [41,42], these results sug-
gest that methylation in non-promoter, non-CpGi
regions may have novel, currently undefined roles in reg-
ulating development. A recent report also indicates dif-
ferential development-associated methylation within Hox
gene clusters in human [48].
DNA methylation and alternative promoter use
Interrogation of the MeDIP/NimbleGen array data sug-
gests that DNA methylation may be associated with alter-
native promoter use. Analysis of methylation within the
Protocadherin gene clusters on chromosome 18 indicates
extensive methylation within CpGi promoter and non-
CpGi promoter regions, particularly within somatic tis-
sues (Additional file 8 Additional file 9). Some differential
tissue specific methylation in this region is also noted.
Pcdha mRNAs are synthesized by the activation of one of
the alternative promoters on only one of the two chro-
mosomes resulting in monoallelic expression [52].
Although the mechanistic basis for this selection is
unknown, it is hypothesized that it provides a foundation
for neuron adhesive diversity that is required for complex
synaptic interactions [52]. Recent genome-wide methyla-
tion analysis using CHARM [25] also indicates an asso-
ciation between tissue specific DNA methylation and
alternative transcripts. That study indicated that most tis-
sue specific differentially methylated regions were located
in CpGi shores and that 68% of the shores were within
500 bp of alternative promoter sites.
The impact of T-DMRs and DS-DMRs on gene expression
To understand the biological function of T-DMRs and
DS-DMRs, one obvious approach is to examine their
impact on gene expression. Efforts to address this ques-
tion at a genome scale is complicated by several factors
that can obscure correlations.
First, one gene may be subjected to DNA methylation
in multiple regions with the T-DMR or DS-DMR in
question being just one of those. Therefore, the level of
gene expression may depend on methylation status in
other regions of the gene. Second, existence of multiple
splicing isoforms, particularly those associated with alter-
native promoters, as well as the use of multiple expres-
sion probes for the same gene makes this one-gene vs.
one DMR association analysis very challenging. Last but
not least, DNA methylation is not the only factor affect-
ing the gene expression. In other words, the lack of DNA
methylation in one of the promoter region does not
necessarily confer gene activation, as the expression can
be limited by other factors, for instance the lack of the
required transcriptional factor(s). These complications
may be responsible for the highly diverse situations we
observed between the occurrence of T-DMRs/DS-DMRs
and the expression level of their associated genes on a
gene-by-gene basis. Despite these complications, our pre-
liminary analysis does seem to reveal a few novel insights.
First, it appears that T-DMRs are associated with lower
gene expression in non-CpGi promoter regions. Second,
there may be some differences between T-DMRs and
DS-DMRs from earlier developmental stages in the man-
ner they impact gene expression. Certainly, extensive
data analysis using more data sets representing more tis-
sues, as well as experimental validation is needed to con-
firm these observations.
Conclusions
Overall, our results indicate that there are extensive dif-
ferences in DNA methylation between adult tissues and
within tissues during development. These results indi-
cate that differential DNA methylation is a dynamic pro-
cess involving both methylation and demethylation
events. The prominence of demethylation in adult tis-
sues of genomic regions that are methylated at earlier
Liang et al. BMC Genomics 2011, 12:231
http://www.biomedcentral.com/1471-2164/12/231
Page 11 of 16stages of development was particularly striking. Even
though proliferative changes in cell populations may
underlie many apparent methylation differences during
development, the results still indicate that extensive dif-
ferences in methylation status are associated with devel-
opment. Although the majority of the methylation
differences were associated with non-CpGi promoter
regions, there were also many methylation differences
associated with non-promoter regions that may have
novel roles in regulating development.
Methods
Growth of ES cells and collection of tissues, DNA and
RNA preparations
ES cells were grown as previously described [32,53]. C57
BL/6J mice were purchased from Jackson Laboratory and
maintained less than three generations in the department
of Laboratory Animal Research facility at Roswell Park
Cancer Institute under an approved IACUC protocol.
Conventional pair breeding was performed, the plug was
confirmed and then the male mouse was removed from
the breeding cage after one day. Pregnant mice were sacri-
ficed for embryo collection 15 days later (E15). Embryonic
sacs were kept in PBS solution on ice. After the quick con-
firmation of development stage, embryos were subjected
to dissection under the microscope (Leica MZ-125). Brain,
heart, liver and testis tissues were carefully obtained from
male embryos (verified later, see following). Male new
born (NB) mice were collected within 24 hours after deliv-
ery and used for collection of the same tissues. 12 weeks
old adult male mice (AD) were also used for adult tissue
collection as described before [32]. Tissues and cells were
immediately snap-frozen in liquid nitrogen and stored at -
80 °C until use.
The sex of embryonic mice was determined by using Y
chromosome marker and the Zfxy genotyping. PCR was
performed to confirm sex by using primers (Zfxya-’:
AGCTGTTTCATAGTCACAGAACTTAC, Zfy-’-11:
CGAATGTGATGACTGTAGGAAGAATC, and Zfx-5’-2:
AGAAAGCCATAGAATGCGATGAGTGC). PCR results
showing multiple bands indicated male mice, which were
then used in this study. Mixtures of 6 male mouse tissues
were used for DNA isolation for E15 and NB analysis
since it was not feasible to obtain enough DNA from a sin-
gle E15 or NB animal. Adult tissues were collected from
two separate animals. DNA was then prepared from 2
separate mixtures (E15 and NB) and 2 separate adults.
Genomic DNA from all tissue samples was extracted
using the DNeasy Kit (QIAGEN) according to Qiagen
protocol.
Sequenom MassARRAY quantitative methylation analysis
Sequenom MassARRAY quantitative methylation analysis
was performed as previously described [32] using
protocols provided by Sequenom (see Additional file 13
for a list of primers used). All oligonucleotides were pur-
chased from Integrated DNA Technologies (Coralville,
IA). Amplification of 1 μl bisulfite-treated DNA (~20 ng/
ml) was performed using HotStar Taq Polymerase (Qia-
gen) in a 5 μl reaction volume using PCR primers at a
200 nM final concentration. PCR amplification was per-
formed with the following parameters: 94 °C for 15 min
hot start, followed by denaturing at 94 °C for 20 s,
annealing at 56 °C for 30 s, extension at 72 °C for 1 min
for 45 cycles, and final incubation at 72 °C for 3 min.
PCR products were processed for MassARRAY analysis
according to the manufacturer’s instructions (Sequenom
hMC) by the Microarray and Genomics Core Facility at
Roswell Park Cancer Institute. In the mass spectrum, the
relative amount of methylation can be calculated by com-
paring the signal intensity between mass signals of
methylated and non-methylated template DNA. Each
spot is ionized 50× per seconda tf i v ed i f f e r e n tr a s t e r s
with all resultant methylation calls performed by the Epi-
Typer software v1.0 (Sequenom). All data is transferred
and stored in an Oracle database for tabulation. A mini-
mum of two independently derived tissue DNAs were
analyzed.
Methylated DNA Immunoprecipitation analysis: MeDIP [33]
High-quality genomic DNA isolated from E15, NB and
AD mouse tissues, was digested with MseI (TTAA)
(New England Biolabs) to produce small fragments (200
- 1,000 bp) while keeping CpGi regions intact. Fragmen-
ted DNA was heat denatured to produce single-stranded
DNA, and a portion of the denatured DNA stored as
control (input) DNA. Monoclonal mouse anti 5-methyl
cytidine ( Eurogentec) was used to immunoprecipitate
methylated DNA fragments. The immune complexes
were captured with Protein A Agarose beads (Invitro-
gen). Complexes were washed to remove nonspecifically
bound material. Following elution of bound complexes,
ethanol precipitation, and resuspension of MeDIP DNA,
a small aliquot of DNA and control input DNA were
used to amplify a known methylated DNA region and a
known unmethylated DNA region by real-time PCR.
The primers of Pst4, Pst6 and Pst21 that were identified
by RLGS previously [32] were used in enrichment mea-
surements according to the manufacturer’s instructions
(NimbelGen). Ratios between the MeDIP and input
values are defined and normalized against a known
unmethylated control sequence. After validating the
enrichment of MeDIP DNA, MeDIP DNA and control
input DNA were amplified by whole-genome amplifica-
tion kit (Sigma Aldrich), followed by purification (QIA-
GEN Quick PCR Purification Kit) and then sent to
NimbleGen for Microarray hybridization according to
their standard protocol for the array.
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Raw data processing and methylation peak identification
The first stage of raw data processing was performed by
NimbleGen as part of its commercial service (Detailed
description is available at http://www.nimblegen.com).
In brief, it involves the following 4 steps. 1) Signal
extraction: Signal intensity data is extracted from the
scanned images of each array using NimbleScan. 2) Cal-
culation of log2 ratio: For each feature on the array, a
corresponding scaled log2-ratio representing the ratio of
the input signals for the experimental and test samples
that were co-hybridized to the array is computed and
scaled to center the ratio data around zero. Scaling is
performed by subtracting the bi-weight mean for the
log2-ratio values for all features on the array from each
log2-ratio value. 3) Calculation of P score: From the
scaled log2-ratio data, a fixed-length window (750 bp) is
placed around each consecutive probe and the one-
sided Kolmogorov-Smirnov (KS) test is applied to deter-
mine whether the probes are drawn from a significantly
more positive distribution of intensity log-ratios than
those in the rest of the array. The resulting score for
each probe, called P score, is the -log10 p-value from the
windowed KS test around that probe. 4) Identification
of methylation peaks: This is performed by searching for
regions containing at least 2 consecutive probes with a
Ps c o r e≥ 2. Peaks within 500 bp of each other are
merged. The processed data (P Scores) and raw data
(log2 ratios) for all 24 involved samples have been
deposited in GEO at NCBI under accession# GSE21415.
Identification of methylation peaks shared by or unique to
a given set of samples
This part was mostly done using an in-house bioinfor-
matics tool based on the following criteria and definition:
1) A methylation peak of a sample is the methylated region
shared between the two biological replicates of the same
sample. This requirement applies to all categories of
methylation peaks; 2) A methylation peak unique to a sam-
ple or a group of samples is a methylated region that only
appeared in the sample or group. It was further examined
to ensure that this region does not overlap with any raw
peaks (those of individual replicates from NimbleScan) of
other individual samples; 3) A peak shared by one or more
but not all samples in a group; 4) A methylation peak com-
mon to a group of samples. In identifying these methyla-
tion peaks, it is often necessary to break the larger
overlapping raw peaks into several sub-peaks such that one
part of an original peak may be identified as a common
peak and another part as a unique peak.
Defining the location category of DMRs
To define the location of a methylation peak in context
of a gene, we used the annotation data of promoters
and CpGi regions of mouse genome provided by
NimbleGen, which is in turn based on UCSC February
2006 (mm8) genome freeze for annotation of CpGi
regions and mRNAs and their genome coordinates.
Using an in-house PERL script, each peak is assigned
into one of the following categories: 1) CpGi promoter,
located within 500 bp distance to a CpGi and is within
an annotated promoter (1 kb flanking each side of the
transcription start site or TSS); 2) non-CpGi promoter,
located within a promoter without CpGi or more than
500 bp away from any CpGi in the promoter; 3) Intra-
genic CpGi, located within 500 bp of a CpGi that locates
in a gene (excluding the promoter as defined above); 4)
Intergenic CpGi, located within 500 bp from a CpGi
that is more than 2 kb from any annotated genes. The
assignment is done in the above order of the four cate-
gories such that a given DMR belongs to only one cate-
gory with the CpGi promoter having a higher priority
over the rest of the categories and so on. For DMRs in
tiling regions, two additional categories were added as
non-CpGi intergenic and non-CpGi intragenic. DMRs in
tiling regions were identified by collecting all DMRs
located within the tiling regions, which include Chr6:
51,984,676-52,408,211, Chr7: 142,162,309-143,552,631
and Chr17: 12,525,776-12,614,350.
Gene ontology analysis and other statistical analyses
For DMRs associated with a gene (including CpGi pro-
moter, non-CpGi promoter, and Intragenic CpGi), we
examined whether a statistically significant enrichment of
gene ontology - a given gene list can be observed using
the DAVID tool [54]. A significant enrichment requires a
Benjamini adjusted P value no more than 0.05. Scatter
plots were generated using R http://www.r-project.org/
a n dH e a tm a p so fPs c o r e sw e r eg e n e r a t e du s i n gM e V
http://www.tm4.org/mev/[55].
Assessment of the MeDIP data quality and validation of
MeDIP methylation peaks
To evaluate the overall quality of the MeDIP data, we
plotted the log2 ratios (methylation signals between the IP
DNA and the input DNA) and P score of all probes
between biological replicates representing different sam-
ples of the same tissues from different animals. The scatter
plots of log 2 ratios as shown in Additional file 14 indi-
cates that a good level of consistency was seen among bio-
logical replicates for all examined tissues (Additional file
4), considering these represented both biological and tech-
nical replicates (Pearson Coefficient R = 0.68 to 0.88 with
over half being > 0.8). The Pearson Coefficient between
replicates is improved in all cases, ranging from 0.75 to
0.94, when P score was used (Additional file 4), on which
the peak call was based, indicating some sporadic noise
was removed by considering the signal level of neighbor-
ing probes in a larger window.
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Page 13 of 16We previously identified T-DMRs using Restriction
Landmark Genomic Scanning (RLGS) [19,32], and some
of these RLGS T-DMRs were used as internal controls
for the quality of IP DNA prior to the array hybridiza-
tion. Quantitative PCR analysis of input and IP DNA
samples indicated that the IP DNA from the appropriate
tissue was enriched for DNA sequences previously
shown to have tissue specific DNA methylation (pre-
sence or absence of methylated DNA fragments at Pst6
and Pst21 were confirmed prior to the hybridization;
data not shown). Additional file 15 shows the results of
MeDIP methylation analysis in the regions of four pre-
viously identified RLGS T-DMRs (Pst4, Pst10, Pvu4 and
Pvu5) that were confirmed by Sequenom MassArray
quantitative methylation analysis [32]. These results are
consistent with both RLGS analysis and the Sequenom
analysis of bisulfite treated DNA [32]. Among the 68
RLGS-TDMRs, 38 overlap with the probes on the array
(allowing a distance of 750 bp the window size we used
for peak identification), of which 27 overlap with the
MeDIP DS-DMRs or T-DMRs. Among the 11 not
picked up by MeDIP, 5 are in the repetitive regions and
would not be included on the array. Therefore, the sen-
s i t i v i t yl e v e lo fo u rM e D I Pi nr e f e r e n c et oR L G Si s2 7 /
33 or 82%.
Sequenom MassArray quantitative methylation analysis
of bisulfite treated DNA was performed as an additional
means to confirm DNA methylation peaks obtained by
MeDIP/NimbleGen Array for both selected and randomly
chosen MeDIP methylated regions. The Sequenom Mas-
sArray results were consistent with the MeDIP results in
19 of 23 peaks that were evaluated (18 randomly chosen
and 5 selected peaks). An example of the Sequenom Mas-
sArray results for a CpGi promoter region is shown in
Figure 1, and for a randomly selected non-CpGi promoter
region (Additional file 16) indicating the two methods are
in agreement.
We also interrogated MeDIP data within imprinted
regions that are known to be methylated in somatic tis-
sues. Almost the entire imprinted region on Chr 7 that
includes the Kcnq1 gene is represented in a tiling array
(1,390 kb) on the NimbleGen promoter + CpGi array. A
40 kb portion of the Kcnq1 that contains KvDMR is
shown in Additional file 2. The KvDMR is an imprinted
control region of approximately 2 Kb (boxed region)
that is maternally methylated and has previously been
shown to be unmethylated in sperm [56]. Consistent
with these earlier results, the MeDIP/NimbleGen array
results clearly indicate that DNA from the testis is not
methylated in this region. Similarly, the imprinting con-
trol region associated with Igf2r is also unmethylated in
testis [57] (Additional file 17). Since only the maternal
allele is methylated in these imprinted regions, MeDIP
is capable of detecting methylation in a single allele.
Analysis of relationship between T-DMRs/DS-DMRs and
gene expression
Two gene expression data sets, GSE9954 and GSE13149,
that are deemed suitable for our purpose were identified
and retrieved from the NCBI GEO database. For
GSE9954, we used the normalized expression values pro-
vided in GEO by the authors and performed the distribu-
tion pattern and statistical analysis of expression for genes
associated with all T-DMRs from each tissue. Specifically,
for T-DMRs from each of the 3 location categories, i.e.,
the CpGi promoter, the non-CpGi promoter and intra-
genic CpGi, in a tissue, we compared the expression level
and distribution pattern of their associated genes in that
tissue with that of the same set of genes in three other tis-
sues, as well as gene associated T-DMRs in other two loca-
tion categories, based on box plot and t-test using the R
package. For GSE13149, the raw Cel files were down-
loaded from GEO for samples at E15.5, Day0 and adult
mice, which presumably correspond to our E15, new born
(NB) and adult samples, and were processed for gcRMA
and quantile normalization using the BioConductor R
page. The expression data in association with liver DS-
DMRs was analyzed in a manner similar to T-DMRs.
Additional material
Additional file 1: E15 and ES T-DMRs.
Additional file 2: MeDIP/NimbleGen Promoter + CpGi Array (Tiling
region): Methylation analysis of KvDMR region. The scaled log2 ratio of
the 40 Kb region on chromosome 7 near KvDMR is shown. The numbers on
the top indicate the genomic position. The rectangle indicates the position
of the KvDMR that includes two CpGi regions. Two independent tissues
were taken from different mice. Previous studies indicate that the KvDMR is
methylated in somatic tissue and unmethylated in sperm [57].
Additional file 3: T-DMRs in tiling regions.
Additional file 4: Pearson Coefficient and common peak number
between replicates.
Additional file 5: a: Overlaps between different tissues for DS-DMRs
with testis excluded; b:Overlaps between tissues for DMRs shared
by all developmental stages in a tissue.
Additional file 6: T-DMRs within the Hoxa gene cluster. The MeDIP
methylation profile for the Hoxa gene cluster within the 52.08 to 52.20 Mb
region on chromosome 6 is shown. The locations of CpGi regions, Hoxa
gene transcripts from a1 to a13 and transcription direction are indicated.
The numbers on the bottom from 1 to 8 indicate the position of
methylation peaks (represented by the log2 ratio) corresponding to those
listed in Additional file 7.
Additional file 7: Methylation peaks locations in the Hoxa gene
cluster.
Additional file 8: DNA methylation and alternative promoters for
Pcdha genes. Methylation profile for Pcdha genes is shown in a similar
manner as in Additional file 2. See also Additional file 9.
Additional file 9: Methylation peaks locations in the Protocadherin
gene cluster.
Additional file 10: Relationship between T-DMRs and expression of
their associated genes. The expression of the genes associated with
liver unique T-DMRs were compared to that of the same gene set in the
three other tissues broken down into the CpGi promoter (CpGi_P), non-
CpGi promoter (NCpGi_P) and intra-genic CpGi (Intra_CpGi) groups using
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Page 14 of 16boxplots (panel A, B and C, respectively). Comparison was also made for
T-DMRs associated genes across different location groups within liver
(Panel D). The p values of pairwise t-tests between liver and each of the
other tissue (panels A-C) and between each pair of location groups
(panel C) are provided on the right side of the boxplots with those no
great than 0.05 shown in bold font. “NDMR” in panel C refers to genes
associated with all genes not associated with liver unique T-DMRs.
Additional file 11: Gene ontology for T-DMRs in adult.
Additional file 12: Gene ontology for DS-DMRs subjected to
methylation or demethylation in adult.
Additional file 13: A list of Sequenom MassARRAY primers used for
Validation.
Additional file 14: Scatter plots of log2 ratios of two replicates for
brain tissues at E15, NB, and AD stages. Log2 ratio of all probes for
the two replicate samples of brain at all stages were plotted. In each
plot, data points in red rectangular area are those showing log2 ratio ≥ 1
(i.e. ratio ≥2) in both samples. Pearson Coefficient and the common
methylation peak number are provided on the top of each plot.
Additional file 15: MeDIP/NimbleGen Promoter + CpGi Array:
Methylation analysis of RLGS T-DMR loci. The MeDIP methylation
profile including scaled log2 ratio and methylation peaks of four RLGS T-
DMR loci are shown (Pst4, Pst10, Pvu4 and Pvu5). The loci were identified
as T-DMRs by RLGS [32]. The CpG island, genomic location, relevant gene
and the direction of each transcript are indicated. The log2 ratio is the
ratio of signals for the input and immunoprecipitated DNA test samples
that were co-hybridized to the array. RLGS T-DMRs were also confirmed
by Sequenom MassARRAY ([32], and data not shown).
Additional file 16: Comparison of methylation data between MeDIP/
NimbleGen Promoter + CpGi Array and Sequenom MassARRAY: Non
CpGi promoter region (randomly selected). Data similar to that
presented in Figure 1 for a randomly selected locus, the non-CpGi
promoter region of Gm1070 that is methylated in liver and ES, but not in
testis.
Additional file 17: MeDIP/NimbleGen Promoter + CpGi Array (Tiling
region): Methylation analysis of Igf2r imprint control region. The
MeDIP methylation profile of a region on chromosome 17 that includes
Igf2r and BC009123 is shown. The numbers on the top indicate the
genomic position. The CpGi in the rectangle is located close to the
promoter region of BC009123 and the second intron of Igf2r. Methylation
within the CpGi is associated with repression of transcription of Airn
antisense RNA located somewhat downstream of TSS for BC009123. The
imprinting control region (rectangle) is monoallelically methylated in
somatic tissue and unmethylated in testis [57].
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